Elsevier Launches International Journal for Parasitology: Drugs and Drug Resistance

June 22, 2011

AMSTERDAM, June 22, 2011 /PRNewswire/ –

New Open Access Journal Dedicated to Collaborations and Cutting-Edge
Research in Parasitology

Elsevier, a world-leading provider of scientific, technical and medical
information products and solutions, in association with the Australian
Society for Parasitology [http://parasite.org.au ], is pleased to announce
the launch of a new journal, International Journal for Parasitology: Drugs
and Drug Resistance. The new electronic open access journal is closely
affiliated with the leading parasitology journal, International Journal for
Parasitology, and will address a critical area of research, covering
anti-parasite drug identification, development and evaluation, and parasite
drug resistance. The journal’s remit also includes research into natural
products as anti-parasitic agents, and bioactive parasite products.

Prof Terry Spithill, President of the Australian Society for
Parasitology, said, “The Society is delighted to have fostered the founding
of this new Journal which we anticipate will provide a stellar forum for the
dissemination of original discoveries in the pharmacological control of
parasites of human and veterinary significance.”

Original research includes the development of novel and innovative
concepts and ideas, as well as experimental and observational science that
raises new hypotheses. The Journal encourages critical comment and debate on
matters of current controversy in the area of parasite drug resistance and
anti-parasite drugs via “Current Opinions”. Studies can be aimed at
unicellular or multicellular parasites of human or veterinary importance.

“We are delighted to continue our excellent relationship with the
Australian Society for Parasitology, and are confident that IJP:DDR will
quickly establish itself as the leading journal in its field,” added Dale
Seaton, Executive Publisher for Elsevier. “In addition, by utilizing the
open access model option for this title, Elsevieris enabling the broadest
possible access to quality research content in a sustainable way that meets
the society’s needs.”

More information about the scope of articles accepted for submission are
available on the Journal’s website
[http://www.elsevier.com/wps/find/journaldescription.cws_home/726218/description#description ]
. Article submissions for IJP:DDR can be made at


About Elsevier

Elsevier is a world-leading provider of scientific, technical and
medical information products and services. The company works in partnership
with the global science and health communities to publish more than 2,000
journals, including The Lancet (http://www.thelancet.com) and Cell
(http://www.cell.com), and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier’s online solutions include
SciVerse ScienceDirect (http://www.sciencedirect.com), SciVerse Scopus
(http://www.scopus.com), Reaxys (http://www.reaxys.com), MD Consult
(http://www.mdconsult.com) and Nursing Consult (
http://www.nursingconsult.com), which enhance the productivity of
science and health professionals, and the SciVal suite (
http://www.scival.com) and MEDai’s Pinpoint Review (
http://www.medai.com), which help research and health care institutions
deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (
http://www.elsevier.com) employs 7,000 people worldwide. The company is
part of Reed Elsevier Group PLC (http://www.reedelsevier.com), a
world-leading publisher and information provider, which is jointly owned by
Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext
Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock

        Media contact
        Harald Boersma
        Senior Manager, Corporate Relations, Elsevier

SOURCE Elsevier

Source: newswire

comments powered by Disqus